EMOXYPINE SUCCINATE 30ML LIQUID (100MG/ML 3000MG BOTTLE)

$49.99

Emoxypine Succinate is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

×

jQuery(“.coabutton”).on(‘click’, function() {
jQuery(“.custom-model-main”).addClass(‘model-open’);
});
jQuery(“.msdsbutton”).on(‘click’, function() {
jQuery(“.custommsds-model-main”).addClass(‘model-open’);
});
jQuery(“.close-btn, .bg-overlay”).click(function(){
jQuery(“.custom-model-main”).removeClass(‘model-open’);
jQuery(“.custommsds-model-main”).removeClass(‘model-open’);
});

Also Available In:
Powder Option >>

Description

Emoxypine Succinate Nootropic Liquid

 

CAS Number 127464-43-1
Other Names Mexidol Succinate, Mexifin Succinate, UNII-2R985002CT, 2R985002CT, mexiprim, Emicidine
IUPAC Name butanedioic acid;2-ethyl-6-methylpyridin-3-ol
Molecular Formula C₈H₁₁NO
Molecular Weight 137.18
Purity ≥99% Pure (LC-MS)
Liquid Availability 30mL liquid (100mg/mL, 3000mg bottle)
Powder Availability 10 grams, 30 grams
Storage Store in cool dry environment, away from direct sunlight.
Terms All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

What is Emoxypine Succinate?

Emoxypine succinate is a nootropic drug originally developed in Russian for the purpose of treating a variety of neurological, cognitive, and cardiovascular impairments. Emoxypine succinate consists of two functionally significant compounds: succinate and 2-ethyl-6-methyl-3-hydroxypyridine. The latter of the two compounds determines the membranotropic and antioxidant effects of the drug, as well as its ability to regulate receptor and ion channel functioning and reduce glutamate excitotoxicity. Succinate is related to the antihypoxic effects of the compound due to its ability to maintain the succinate oxidase FAD-dependent link to the Krebs cycle. This inhibits NAD-dependent oxidases under hypoxic conditions and allows for maintained energy production in the cell [1]. It is important to note that the hydroxypyridine structure and succinate derivatives of the nootropic have a low molecular weight allowing for several pharmacokinetic advantages related to the compound’s ability to penetrate the blood brain barrier, and elicit antihypoxic, cardioprotective, and neuroprotective effects. Current research has identified iron-chelating properties of the nootropic, indicating that Emoxypine succinate may be used to treat hemochromatosis, thalassemia, and neurodegenerative disorders such as Alzheimer’s disease [2].

 

File Name View/Download
2026-03-11-Umbrella-Labs-Emoxypine-Succinate-Certificate-of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)

 

Additional information

Options

10 Grams Powder, 30 Grams Powder, 30mL Liquid 100mg/mL 3000mg bottle

Reviews

There are no reviews yet.

Be the first to review “EMOXYPINE SUCCINATE 30ML LIQUID (100MG/ML 3000MG BOTTLE)”

Your email address will not be published. Required fields are marked *